Module 2: HCR 561: Discussion 2

Module 2: HCR 561: Discussion 2

In March 2006, a Phase I clinical trial was conducted at Northwick Park Hospital in London to test a drug called TGN1412, developed by the German company TeGenero. The study was sponsored by Parexel, a U.S.-based clinical research organization. The research aimed to test the safety of the immune-boosting drug in humans. Eight healthy male volunteers participated, but six of them experienced life-threatening side effects, including organ failure, within hours of receiving the drug. The trial was meant to test the drug’s ability to treat conditions like leukemia and rheumatoid arthritis by stimulating the immune system (Suntharalingam et al., 2006). (Link: Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412 | New England Journal of Medicine

The cultural climate in 2006 supported rapid innovation in biotechnology and medicine. There was growing public and governmental interest in accelerating drug development. However, this also led to less scrutiny on trial safety in some cases. The pharmaceutical industry was under pressure to deliver breakthrough treatments, and clinical trial outsourcing was common. In this context, researchers may have felt pressure to move quickly through early-phase testing, possibly contributing to ethical oversights (Meslin & Johnson, 2008). Several ethical concerns emerged from this trial. The most significant was that the drug caused catastrophic immune reactions in all participants, raising concerns about inadequate preclinical testing and poor risk assessment.

This study violated the Declaration of Helsinki, which states that research risks must be minimized and fully explained (Ashcroft, 2008). It also breached the Common Rule, especially regarding informed consent and subject protection (Porter & Koski, 2008). Participants were not fully informed about the drug’s novel mechanism and the potential severity of side effects. Both the Declaration of Helsinki and the Common Rule were in effect in 2006. To make the trial more compliant, researchers should have conducted more extensive animal testing and used a staggered dosing schedule for human participants. Improved risk communication and ethical review could have reduced harm and ensured better protection for the volunteers (Emanuel, Wendler, & Grady, 2008).

References

Ashcroft, R. E. (2008). The declaration of Helsinki. The Oxford textbook of clinical research ethics, 141-148.

Emanuel, E. J., Wendler, D., & Grady, C. (2008). An ethical framework for biomedical research. Oxford textbook of clinical research ethics (pp. 123–135). Oxford University Press.

Meslin, E. M., & Johnson, S. (2008). National bioethics commissions and research ethics (pp. 187-197). The Oxford textbook of clinical research ethics.

Porter, J. P., & Koski, G. (2008). Regulations for the Protection of Humans in Research in the United States (Vol. 156). New York/Oxford: Oxford University Press.

Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New England Journal of Medicine, 355(10), 1018-1028. DOI: 10.1056/nejmoa063842

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

Module 2: HCR 561: Discussion 2